Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

Thumbnail
View/Open
Full Text
Date
2012-04-01
Author
Giles, Francis
Rizzieri, David
Ravandi, Farhad
Swords, Ronan
Jacobsen, Tove Flem
O’Brien, Susan
Metadata
Show full item record
Usage
This item's downloads: 0 (view details)
Cited 15 times in Scopus (view citations)

Recommended Citation
Giles, Francis; Rizzieri, David; Ravandi, Farhad; Swords, Ronan; Jacobsen, Tove Flem; O’Brien, Susan (2012). Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. Leukemia Research 36 (4), E71-E73
Published Version
URI
http://hdl.handle.net/10379/11635
Collections
Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland